Background and aims: Aspirin is proven to reduce the incidence of Colorectal in Lynch Syndrome (LS). We conducted a survey of aspirin use in gene positive LS patients to assess the prevalence of aspirin use in LS. Method All 975 known gene positive LS patients in New Zealand (NZ) were invited to participate. Results 502 of 975 (51.5%) completed the survey. 290 (57.8%) female, 212 (42.2%) male. 74.3% were over 45 years. 256 people (51.0%) were aware of the potential chemopreventive benefits of aspirin. Overall 119 (23.7%) patients were taking regular aspirin. This increased if a personal history of CRC. 86.6% were taking 100mg Aspirin and only 4% were taking 600mg. 72.2% were taking Aspirin for LS chemoprophylaxis and 31 (25.6%) for cardiovascular or cerebrovascular disease. Median duration of Aspirin use 4 years; range 1 month to 30 years. 43 (48.8%) of those taking Aspirin were doing so due to recommendation from NZFGCS, 35 (39.8%) due to recommendation from other medical professionals and 11 (12.5%) due to own research including social media and Facebook groups. Of those currently not taking aspirin, 48 (12.5%) had previously taken aspirin regularly. The most common reason given for stopping was due to side effects (37.5%). Conclusions Only 51 of LS patients in NZ were aware of the potential benefits of aspirin in reducing risk of CRC. Only 23.7% of gene positive LS patients were regularly taking aspirin. Having a personal previous diagnosis of CRC increased this significantly to 32.6%. There is still urgent need for ongoing targeted patient education about this important aspect of colorectal cancer prevention in LS in NZ.